These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 26044060)

  • 1. Comment on "deferiprone versus deferoxamine in thalassemia intermedia: results from a 5-year long-term Italian multicenter randomized clinical trial".
    Saliba AN; Taher AT
    Am J Hematol; 2015 Sep; 90(9):E192-3. PubMed ID: 26044060
    [No Abstract]   [Full Text] [Related]  

  • 2. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deferiprone versus deferoxamine in patients with thalassemia major: a randomized clinical trial.
    Maggio A; D'Amico G; Morabito A; Capra M; Ciaccio C; Cianciulli P; Di Gregorio F; Garozzo G; Malizia R; Magnano C; Mangiagli A; Quarta G; Rizzo M; D'Ascola DG; Rizzo A; Midiri M
    Blood Cells Mol Dis; 2002; 28(2):196-208. PubMed ID: 12064916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with deferiprone and desferrioxamine in thalassemia major.
    Loukopoulos D
    Haematologica; 2005 Oct; 90(10):1304-5. PubMed ID: 16219564
    [No Abstract]   [Full Text] [Related]  

  • 5. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies.
    Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Magnano C; Rizzo M; Caruso V; Gerardi C; Argento C; Campisi S; Cantella F; Commendatore F; D'Ascola DG; Fidone C; Ciancio A; Galati MC; Giuffrida G; Cingari R; Giugno G; Lombardo T; Prossomariti L; Malizia R; Meo A; Roccamo G; Romeo MA; Violi P; Cianciulli P; Rigano P
    Blood Cells Mol Dis; 2009; 42(3):247-51. PubMed ID: 19233692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance.
    Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ
    Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.
    Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI
    Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined therapy with desferrioxamine and deferiprone in thalassemic patients: effect on urinary iron excretion.
    Kattamis A; Kassou C; Berdousi H; Ladis V; Papassotiriou I; Kattamis C
    Haematologica; 2003 Dec; 88(12):1423-5. PubMed ID: 14687998
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
    Balocco M; Carrara P; Pinto V; Forni GL
    Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term use of deferiprone significantly enhances left-ventricular ejection function in thalassemia major patients.
    Maggio A; Vitrano A; Lucania G; Capra M; Cuccia L; Gagliardotto F; Pitrolo L; Prossomariti L; Filosa A; Caruso V; Gerardi C; Campisi S; Cianciulli P; Rizzo M; D'Ascola G; Ciancio A; Di Maggio R; Calvaruso G; Pantalone GR; Rigano P
    Am J Hematol; 2012 Jul; 87(7):732-3. PubMed ID: 22622672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone (GPO-L-ONE(®) ) monotherapy reduces iron overload in transfusion-dependent thalassemias: 1-year results from a multicenter prospective, single arm, open label, dose escalating phase III pediatric study (GPO-L-ONE; A001) from Thailand.
    Viprakasit V; Nuchprayoon I; Chuansumrit A; Torcharus K; Pongtanakul B; Laothamatas J; Srichairatanakool S; Pooliam J; Supajitkasem S; Suriyaphol P; Tanphaichitr VS; Tuchinda S
    Am J Hematol; 2013 Apr; 88(4):251-60. PubMed ID: 23460233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 15. Sequential alternating deferiprone and deferoxamine treatment compared to deferiprone monotherapy: main findings and clinical follow-up of a large multicenter randomized clinical trial in -thalassemia major patients.
    Pantalone GR; Maggio A; Vitrano A; Capra M; Cuccia L; Gagliardotto F; Filosa A; Romeo MA; Magnano C; Caruso V; Argento C; Gerardi C; Campisi S; Violi P; Malizia R; Cianciulli P; Rizzo M; D'Ascola DG; Quota A; Prossomariti L; Fidone C; Rigano P; Pepe A; D'Amico G; Morabito A; Gluud C
    Hemoglobin; 2011; 35(3):206-16. PubMed ID: 21599433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Post transfusionnal iron overload].
    Rose C
    Rev Prat; 2006 Dec; 56(19):2141-5. PubMed ID: 17416052
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reversal of heart failure in thalassemia major by combined chelation therapy: a case report.
    Tsironi M; Deftereos S; Andriopoulos P; Farmakis D; Meletis J; Aessopos A
    Eur J Haematol; 2005 Jan; 74(1):84-5. PubMed ID: 15613114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
    Wu KH; Chang JS; Tsai CH; Peng CT
    Ann Hematol; 2004 Jul; 83(7):471-3. PubMed ID: 14658011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective randomized controlled trial on the safety and efficacy of alternating deferoxamine and deferiprone in the treatment of iron overload in patients with thalassemia.
    Galanello R; Kattamis A; Piga A; Fischer R; Leoni G; Ladis V; Voi V; Lund U; Tricta F
    Haematologica; 2006 Sep; 91(9):1241-3. PubMed ID: 16956824
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.